Loadingβ¦
MARKETS
TOOLS
LEARN
Equiscale Β· Syntellia LLC
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
5-year financial trends
No historical performance data available.
No growth data available
No growth data available.
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
No historical growth data available.
Income statement, balance sheet, and cash flow as reported
No financial statement data available.
Sector peers ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| KALVthis co. | KALV | - | - | - | - | - |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Neonode Inc. | NEON | $31M | 3.66 | 1.26 | 34.4% | 0.79 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | -1.59 | 1.38 | -87.0% | -0.31 |
| GoHealth, Inc. | GOCO | $21M | -0.08 | 0.56 | -678.9% |
| -1.98 |
| Sleep Number Corporation | SNBR | $8M | - | - | 22.8% | 105.20 |
| zSpace, Inc. | ZSPC | $1M | -0.04 | -0.04 | 112.8% | -0.75 |
| Trinseo PLC | TSEOF | $0M | -0.00 | -0.00 | 49.7% | 39.40 |
| ACCO Brands Corporation | ACCO | $0M | 0.00 | 0.00 | 6.2% | 5.11 |
| Peer Median | - | -0.04 | 0.56 | 14.5% | 0.24 | |
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, May has averaged the highest return (+0.8%); Jun the lowest (+0.5%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | β | β | β | β | +0.8%Neutral MonthMay 2026: +0.79% | +0.5%Neutral MonthJun 2026: +0.48% | β | β | β | β | β | β |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 1 year of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
